Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Reports Q4 Revenue Increase

SAN FRANCISCO, Jan. 28 - Illumina today reported increased revenue for the fourth quarter of 2002.


The company said its total revenue was $3.9 million in the fourth quarter which ended December 29, up from $800,000 in the same quarter of 2001. Total revenue for the 2002 year was $10 million, compared to $2.5 million in 2001, according to the company.


Illumina reported a net loss of $7.6 million, or $.24 per share, in the fourth quarter 2002 compared to a net loss of $8.2 million, or $.27 per share, in the year-ago period. Total net loss for 2002 was $40.3 million, or $1.31 per share, compared to a net loss of $24.8 million, or $.83 per share, in 2001.


R&D spending for the fourth quarter 2002 was $6.3 million compared to $6.1 million in the same period a year ago. Total R&D spending for 2002 was $26.8 million compared to $20.7 million in 2001.


Illumina also reported $66.3 million in cash and investments at the end of December 2002.


Click here for more information.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.